Richmond Eye Associates Eye Health and Disorders Donald W. Lumpkin, O.D. David M. Bowman, M.D. D. Alan Chandler, M.D. Bryan M. Brooks, M.D. Barry E. Roper, M.D. David W. MacMillan, M.D. Malcolm Magovern, M.D. Harold A. Bernstein, M.D.


Eye Health
and
Eye Disorders

About Lasik

Eye Disorders

Eye News Articles

Vision Tests

Eye Anatomy

About Optics

Eye Links

Special Interest

The Eye and Health

Interactive Sections

Clinical Section

Major Sections On:

Cataract
Glaucoma
Macular Degen
Diabetes
Contact Lens
Drug Side Effects


Eye Symptom Pages:
(13 Categories)


Eye Disorder Pages:
(Over 70 Listed)

Richmond Eye Associates
                         Eye Health and Disorders


Age-related Macular Degeneration (AMD)

Macular degeneration is the leading cause of irreversible severe visual loss in Caucasians age 50 or older in the United States. It has been estimated that this 2.2% of those older than age 65 have worse than 20/200 vision (legally blind) due to this condition. This page discusses the condition known as age-related macular degeneration, or AMD.

Read this important information before proceeding further:

These sections are not intended to replace the professional examination and diagnosis by a physician, and they are presented here purely for informational purposes. All possible diagnoses and treatment options are not covered, and the information discussed should not be taken as a recommendation to self-diagnose and self-treat a condition. A misdiagnosed or improperly treated eye condition can result in a permanent loss of vision, or a permanent loss of function of the eye or visual system. In the case of any eye problem, seek medical attention promptly. This can include emergency room treatment, as well as treatment by a medical physician or eyecare provider.

Topics Include:

For eye anatomy explanations, go to ANATOMY

Note: There are other similar conditions such as ocular histoplasmosis, myopic macular degeneration, and macular degeneration related to angioid streaks and trauma which will not be separately discussed.

Types of Macular Degeneration and Risk factors:

retina The retina is thin lining of nerve cells which lines the inside of the eye. It receives and processes images, and sends these images to the brain via the optic nerve. The macula is a small, but very important part of the retina capable of perceiving the sharpest of images. It is here that our central vision (what we look directly at), our reading vision, and our color vision are received. Without the macula, we would be legally blind, with only peripheral vision (side vision) to guide us.macula An enlarged view of the macula is shown here. The optic nerve is the yellow circle with blood vessels leaving it. The nerve head is about 1.5 mm in diameter. The vessels are retinal arteries and veins which supply the inner layers of the retina. The center of the macula is the small red and yellow dot, called the "fovea". This is our point of visual fixation (with what we look directly at).

The condition known as "age-related macular degeneration" leads to deterioration of the macula, and possible loss of vision. Risk factors for this condition include:

  • Advancing age, over 50 years of age, and especially over 65

  • Caucasian race

  • A history of visual loss related to macular degeneration in the other eye

  • Certain types of retinal deposits, called drusen

  • A family history of macular degeneration

  • Tobacco smoking (especially for the more severe form of macular degeneration)

  • Arteriosclerosis and increased cholesterol, possibly hypertension

  • A diet deficient in anti-oxidant vitamins and minerals

  • A recent study showed that sensitivity to glare and poor tanning ability were markers of increased macular degeneration risk. Interestingly, the study could not demonstrate that sun exposure itself was a risk factor.

Age-related macular degeneration is broadly grouped into two categories: a "dry" form, and a "wet" form. The next section discusses these differences.

"Dry" Macular Degeneration

This form of macular degeneration consists of a slow deterioration of the retina. Deposits form under the retina called "drusen". Drusen may block nutrition from reaching the retina from a highly vascular layer under the retina called the "choroid". The choroid nourishes the outer layers of the retina, while the retinal blood circulation supplies the inner layers. Over time, the retina atrophies, or degenerates, over these area of drusen, and a spotty loss of vision occurs. If more and more of these atrophic areas form and merge together, the macula can take on a moth-eaten appearance, with progressive loss of vision. This usually occurs over a period of many years.

There is no known treatment for this form of macular degeneration. Theoretically, it may help to reduce any risk factors one may have (listed above), but it has not been proven that this will help prevent visual loss. If a person with macular degeneration has a well balanced diet, nutritional supplements may not be necessary. If not, a multi-vitamin is usually recommended (see the section on nutrition below).

"Wet" Macular Degeneration

This is a more severe and rapidly progressive form of macular degeneration. In some cases, the "dry" form of macular degeneration will lead to the "wet" form, but in other cases this form occurs without warning. Between the vascular choroid layer under the retina and the retina itself is a dividing membrane called the "retinal pigment epithelium". If a break occurs in the retinal pigment epithelium, it becomes possible that an abnormal blood vessel could grow from the choroid to directly underneath the retina in the macula. Such a break could occur in an area of drusen, especially drusen that have pigmentation and appear diffuse or fuzzy. When a new blood vessel grows under the retina, it is termed "subretinal neovascularization".
Subretinal neovascularization in the macula can be a surgical emergency. If such a blood vessel is treatable, it should be treated as soon as possible after the diagnosis is made. Symptoms of this condition, otherwise known as "wet" macular degeneration, include:

  • A change in vision, usually a sudden blurring in one eye.

  • Distortion of vision, where straight lines appear crooked in the affected eye.

  • A blind spot appearing in the vision of the affected eye, where things seem to disappear when looked at. Sometimes, a blind spot will occur near to what is being looked at instead.

  • A change in the size appearance of things, with objects appearing to be smaller or larger than with the other eye.

  • For a detailed account of one person's experience with subretinal neovascularization, and for further discussion on this disease, visit Macular Degeneration and Subretinal Neovascularization.

Note: other conditions such as ocular histoplasmosis, myopic macular degeneration, and macular degeneration related to angioid streaks and trauma can lead to subretinal neovascularization.

When an ophthalmologist examines the retina, the blood vessel growing under the retina can often be seen. Other times, there may be hemorrhage in or under the retina, obscuring the view of the vessel. Swelling of the retina can often be observed as well. An additional test, called a fluorescein angiogram, is usually done as immediately as possible to better determine where the new, abnormal blood vessel is and if it can be treated. A fluorescein angiogram is a test done in the office where a pigmented dye is photographed as it passes through the retinal blood vessels. For this test, the eyes are dilated, and initial color photographs are taken of the retina by the photographer. Then, the fluorescein dye is injected into an arm vein by a physician. This is similar to having blood drawn. Once the dye is in, the needle is removed, and the photographs are taken. The dye reaches the eye in a matter of seconds. About 30 photographs are taken between the two eyes over a 10 minute time span. The film is then developed, and the ophthalmologist studies the results. Important information about the leakage and blockage of blood vessels can be gained from this test.

Return to Topic List


Diagnosis and Treatment of Macular Degeneration:

The diagnosis of macular degeneration depends on several factors:

  • A careful history taken by the examiner as to possible risk factors and symptoms of macular degeneration

  • A careful retinal examination to look for evidence of macular degeneration, or for any precursors of it (drusen)

  • Additional tests such as fluorescein angiography and Amsler grid testing (discussed below)

  • Scheduling appropriate follow-up visits, and self-monitoring of vision by the patient

The "Amsler grid" is a small graph-like chart with a central dot. It is useful for testing for distortion of vision. To do the test, the grid is held at normal reading distance (16 inches) with glasses on if needed. With one eye covered, the central dot is looked at. Any missing lines, distorted lines, or other abnormality on the chart is then noted by the patient. The other eye is then tested. This is a way for patients with risk factors for macular degeneration, or with previously treated macular degeneration to monitor their vision for development of "wet" macular degeneration (subretinal neovascularization).

Treatment of "dry" macular degeneration

  • Unfortunately, there is no cure for this form of the disease

  • Vision should be monitored with the Amsler grid for early detection of the "wet" form of macular degeneration

  • Follow-up appointments should be kept as directed

  • Nutritional supplements can be considered

  • Discontinuation of tobacco use in encouraged

Treatment of "wet" macular degeneration

  • Once diagnosed with "wet" macular degeneration, it is implied that subretinal neovascularization is present. If this finding meets certain criteria on the fluorescein angiogram, laser treatment may be able to eliminate the abnormal blood vessel.

  • If treated with laser, a blind spot will result in the vision.

  • The purpose of the laser treatment is to prevent severe loss of vision. Sometimes some loss of vision may occur with the laser treatment in order to prevent further loss of vision.

  • After successful laser treatment, the situation needs to be closely monitored for signs of recurrence. This includes follow-up examinations and possibly more fluorescein angiograms.

  • The Amsler grid should be closely monitored by the patient in both the affected and unaffected eye for a change in vision.

  • Nutritional supplements can be considered.

Return to Topic List

 

New Surgical Treatment Options for Macular Degeneration:

  • Photodynamic Therapy

    Laser treatment of macular degeneration, especially that involving the sharpest area of the vision, has been frustrating, because the laser treatment itself is damaging. Furthermore, the condition often recurs after treatment. A new treatment for the "wet" form of macular degeneration has been FDA approved, called Photodynamic Therapy. The "wet" form of macular degeneration consists of abnormal blood vessels growing under the retina, ultimately leading to distortion in the vision, hemorrhaging, and scarring. If these blood vessels (subretinal neovascular membranes) grow under the most sensitive part of the macula (the fovea), laser treatment of the vessels would also destroy the fovea itself, leading to a loss of central vision. Photodynamic Therapy does not damage the retina overlying abnormal vessels, and offers treatment for an otherwise largely untreatable condition.

    With Photodynamic Therapy, the drug Visudyne (verteporphin) is first injected into an arm vein. After a short waiting period, a light of a specific wavelength is shined upon the part of the retina that contains the abnormal blood vessels. This light, which has the brightness of a flashlight and is non-damaging, activates the injected drug to destroy the abnormal blood vessels, where it accumulates. Thus, the subretinal neovascular membrane is destroyed while sparing the overlying retina. The whole procedure takes about 20 minutes, and is painless.

    The 1 year results of a study looking at the effectiveness and safety of the procedure are favorable. The group of patients treated by Photodynamic Therapy had a 34% better likelihood of retaining vision than an untreated group of patients with the same disorder. In some cases, the vision improved. The procedure did need to be repeated in many patients over a 1 year period to achieve the desired effects. However, there was very little in the way of adverse side effects, with the most common being sensitivity to light for 1 to 2 days.

    The procedure was FDA approved in April 2000. At that time, in 243 patients with mainly "classic" age-related macular degeneration, vision remained stable or improved in 67% when treated with photodynamic therapy. Only 39% of patients who were untreated maintained stable vision. Subsequently, the procedure has been approved for use in similar conditions such as ocular histoplasmosis and myopic macular degeneration. Further evaluation is being done regarding use of Photodynamic Therapy in cases of "occult" membranes under the retina, which are poorly defined.

     

  • Transpupillary Thermotherapy (TTT) This new treatment is similar to Photodynamic Therapy, in that it is not destructive to the overlying retina. If the abnormal vascular membrane is very well defined and identifiable under the retina, it might be treatable using laser, or the newer "photodynamic therapy".  However, in many cases the vessels are poorly outlined and defined under the retina (an "occult" choroidal neovascular membrane), making treatment difficult or impossible.

    Transpupillary thermotherapy (TTT) is an effective treatment of occult wet AMD, according to study results presented at the recent American Academy of Ophthalmology meeting (11/01). More than 100 patients with occult neovascular membranes associated with wet AMD underwent TTT with the IRIS Medical OcuLight SLx laser from IRIDEX Corporation. Some key results:

    • Of the 83 patients available for 6-month follow-up, visual acuity stabilized or improved in 63 patients (76%) and worsened (2 or more line loss) in 20 patients (24%).  Fluid under the retina was reduced in 90% of cases.

    • Of the 48 patients followed for 9 months, visual acuity stabilized or improved in 38 patients (79%).

    In the study, laser treatment consisted of a large laser spot adequate to cover the abnormal vessels, typically 3000-6000 micrometers diameter (3-4 mm), delivered over a period of 1 minute. Patients were evaluated for visual acuity (stable or improved vision was defined as a loss of one line, any improvement in vision or no change in the vision) and the need for additional treatment. The TTT protocol is a Minimum Intensity Protocol (MIP) that uses sub threshold photocoagulation to close CNV while sparing the retina itself. The protocol uses the OcuLight SLx laser and Large Spot Slit Lamp Adapter to produce favorable therapeutic responses in clinical studies with minimal side effects and preservation of vision in patients with occult CNV secondary to AMD.  In cases where a traditional laser is used, the retina would be destroyed along with the abnormal vessels, leading to a loss of vision.

    Retreatments with TTT are needed about 20% of the time, usually within 2 to 4 months.
     

  • Other Surgical Options for macular degeneration include manual removal of abnormal neovascular membranes from under the retina in the operating room. Alternatively, the retina itself can be trans-located away from the abnormal membrane and laid back down on a more healthy area of the eye internally. These techniques are undergoing evaluation in carefully selected patients.

Return to Topic List

 

The Controversy of Nutritional Supplements:

It has been found that people with diets deficient in certain "anti-oxidant" vitamins and minerals may be at increased risk for age-related macular degeneration. However, a well-balanced diet with the possible supplementation of a multivitamin will usually prevent such a deficiency. Should extra doses of these vitamins be taken by those at risk for macular degeneration?

The retina is at risk for light induced damage termed "oxidative" damage. This damage could possibly lead to macular degeneration. The retina has relatively high concentrations of anti-oxidant vitamins and minerals. These substances help to prevent this oxidative damage. These vitamins and trace minerals include:

  • Vitamin A

  • Vitamin E

  • Vitamin C

  • Zinc

  • B-Carotene

  • Other carotenoids found in foods

  • Selenium

Different studies have been done to try to determine if there is any relationship between blood level and dietary intake of these substances with age-related macular degeneration (AMD).  Some earlier studies were fairly inconclusive as to the benefits of dietary supplements on reducing vision loss from macular degeneration:

  • One study showed that high blood levels of Vitamin E were protective for AMD. Similarly, a combination of high blood levels of Vitamin C, Vitamin E, and b-carotene was also protective. However, the study was unable to demonstrate that the consumption of the vitamins themselves helped to preserve vision!

  • Another study found that high blood levels of a combination of carotenoids, Vitamin C, Vitamin E, and selenium had a reduction of risk for the "wet" form of AMD. However, the authors of the study stated that it would be premature to translate these findings into nutritional recommendations.

  • A high dietary intake of zinc was found to be weakly protective in some early stages of AMD in another study , while the intake of carotenoids, Vitamin C, Vitamin E, and of nutritional supplements were found not to be significantly protective.

  • High intake of certain foods containing carotenoids not normally found in vitamin supplements was found to reduce the risk of the "wet" form of AMD. These foods included spinach, collard greens, kale, mustard greens, and turnip greens. Intake of supplemental Vitamin A, C, and E were not found to improve the risk of AMD.

AREDS

The recently published AREDS (Age-Related Disease Study Research Group) results now indicate a definite reduction in risk of vision loss from macular degeneration with dietary supplementation of antioxidants and zinc. This protection was only evident in those already at high risk for the disease at baseline. Those studied with minimal or no evidence of macular degeneration at baseline had such a low rate of vision loss from macular degeneration that no treatment effect could be determined. The antioxidants that were found to be effective were:

  • Antioxidants (500mg vitamin C, 400 IU vitamin E, 15 mg beta carotene)

  • 80 mg zinc, as zinc oxide, and 2mg copper, as cupric oxide

  • Both antioxidants plus zinc together

The antioxidants alone reduced the risk of advanced macular degeneration by 10%, the zinc alone by 14%, and the combination of zinc and antioxidants reduced risk by 21%.  For more information on this study, and potential risks of these vitamin supplements, go to AREDS Results: High-Dose Supplementation with Antioxidants and Zinc Found Beneficial for those at High Risk for Age-Related Macular Degeneration.

Please note that many vitamins, especially Vitamins A and E can be stored by the body, and dangerous side effects can occur when high dosages of these are consumed. In many people, supplementation with high amounts of zinc may lead to anemia. A recent study was terminated because high levels of B-carotene consumption were found to increase the risk of lung cancer in male and female smokers. Thus, vitamin supplementation is not without risk, and one's general physician should be consulted prior to taking vitamin supplements. Finally, the body regulates the absorption of many vitamins and minerals. If the body does not need a particular one of these, it may leave the body undigested.



Return to Topic List

 


 
Footer

At Richmond Eye Associates, "We Specialize in Family Eye Care"
Call 804-270-0330 for an Appointment
Toll Free 1-800-707-0330

Request an Appointment Online  |  Check Here Before Your Appointment | Locations
About Richmond Eye Associates | Specialties |  Insurances Accepted
Laser Vision Correction | Optical Shops  
Eye Disorder Section | Eye News Articles | Eye Health Issues | Special Interest Sections
Contact Richmond Eye Associates | Links | Interactive Sections
Career Opportunities | Public Service Programs | Clinical Section
Home Page | Terms of Use and Copyright
| Notice of Privacy Practices


David W. MacMillan, M.D.     Barry E. Roper, M.D.    D. Alan Chandler, M.D.    Malcolm Magovern, M.D.
Harold A. Bernstein, M.D.     David M. Bowman, M.D.     Bryan M. Brooks, M.D.     Donald W. Lumpkin, O.D.